{
  "query": "adverse free progression grade",
  "studies": {
    "protocolSection": [
      {
        "identificationModule": {
          "nctId": "NCT05653622",
          "briefTitle": "Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-06-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-07-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Glioblastoma Multiforme, Adult"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 75,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02260531",
          "briefTitle": "Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-03-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Breast Cancer", "Brain Tumor - Metastatic"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 36,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02468557",
          "briefTitle": "Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-07-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-04-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Previously Untreated Pancreatic Ductal Adenocarcinoma", "Relapsed/Refractory Pancreatic Ductal Adenocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 16,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03306420",
          "briefTitle": "First-in-Human Study of MS201408-0005A as Single Agent and in Combinations"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-10-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-01-14",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic or Locally Advanced Unresectable Solid Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 15,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06674382",
          "briefTitle": "Haplo-HSCT for Myelofibrosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Myelofibrosis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 39,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01005680",
          "briefTitle": "A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-11"
          },
          "completionDateStruct": {
            "date": "2012-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 256,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01631279",
          "briefTitle": "A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-08"
          },
          "completionDateStruct": {
            "date": "2015-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Unspecified Adult Solid Tumor, Protocol Specific"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 33,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06155383",
          "briefTitle": "Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-11-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 90,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04524689",
          "briefTitle": "Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-10-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 57,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07247396",
          "briefTitle": "CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-11-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-10-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Peritoneal Metastases From Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 12,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05548127",
          "briefTitle": "TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-02-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-03-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 37,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05022342",
          "briefTitle": "Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-10-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-02-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 600,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "100 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07284069",
          "briefTitle": "Senicapoc and Perampanel for Newly Diagnosed Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-02-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-11-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Glioblastoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 36,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01803269",
          "briefTitle": "Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-01-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-03-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Extensive Stage Small Cell Lung Cancer", "Recurrent Small Cell Lung Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 29,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05569512",
          "briefTitle": "Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-10-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-12-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Pediatric Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Months",
          "maximumAge": "39 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03023319",
          "briefTitle": "Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-12-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-05-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Carcinoma, Non-Small-Cell Lung", "Mesothelioma", "Bladder Cancer", "Ovarian Cancer", "Peritoneal Cancer", "Thymoma", "Thymus Cancer", "Uterine Cervical Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 6,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02154737",
          "briefTitle": "Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-07"
          },
          "completionDateStruct": {
            "date": "2020-09-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 24,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04128501",
          "briefTitle": "Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-05-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Bilineal Leukemia", "Acute Biphenotypic Leukemia", "Acute Myeloid Leukemia", "Mixed Phenotype Acute Leukemia", "T Acute Lymphoblastic Leukemia", "Therapy-Related Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 125,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02028507",
          "briefTitle": "Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-03-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-01-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 693,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00283244",
          "briefTitle": "Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-03"
          },
          "completionDateStruct": {
            "date": "2014-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 147,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "70 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06348134",
          "briefTitle": "Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-01-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2036-07-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "HER2-positive Breast Cancer", "Breast Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 74,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07092007",
          "briefTitle": "NWRD09 for HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-06-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Intraepithelial Neoplasia", "Cervical Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "60 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01062399",
          "briefTitle": "Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-12"
          },
          "completionDateStruct": {
            "date": "2022-05-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Brain and Central Nervous System Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 279,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04608487",
          "briefTitle": "Axi-cel in CNS Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-12-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2038-06-14",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Lymphoma", "Lymphoma Cns"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06876844",
          "briefTitle": "Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-12-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-09-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Head and Neck Cancer", "Head and Neck Cancer Squamous Cell Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 24,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02393209",
          "briefTitle": "Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-06-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-01-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 14,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07220187",
          "briefTitle": "Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-05-02",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2036-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Richter Syndrome", "Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma", "Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 102,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03319901",
          "briefTitle": "Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-10-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-04-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 82,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03864419",
          "briefTitle": "Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-10-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-07-26",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Burkitt Lymphoma", "KSHV-associated Multicentric Castleman Disease", "Diffuse Large B-Cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "2 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03741244",
          "briefTitle": "TMZ Plus Apatinib in Newly Diagnosed High-grade Gliomaï¼šRCT"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-05-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-02",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Glioma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 211,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03286244",
          "briefTitle": "Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-03-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Gastric Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 21,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03971409",
          "briefTitle": "Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-07-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Stage III Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Invasive Breast Carcinoma", "Recurrent Breast Carcinoma", "Triple-Negative Breast Carcinoma", "Unresectable Breast Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 150,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00390299",
          "briefTitle": "Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-10-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-11-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Anaplastic Astrocytoma", "Anaplastic Oligodendroglioma", "Mixed Glioma", "Recurrent Glioblastoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 23,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03196232",
          "briefTitle": "Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-09-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-05-29",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Gastric Carcinoma", "Stage IV Esophageal Cancer AJCC v7", "Stage IV Gastric Cancer AJCC v7", "Unresectable Esophageal Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 3,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00975806",
          "briefTitle": "Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-09-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2011-10-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Renal Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 16,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04831567",
          "briefTitle": "Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-02-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-05-13",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Neuroendocrine Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06434064",
          "briefTitle": "Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-01-15",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-11-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Locally Advanced Unresectable Triple-Negative Breast Carcinoma", "Metastatic Triple-Negative Breast Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04458311",
          "briefTitle": "Abiraterone Acetate in Combination With Tildrakizumab"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-12-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-11-15",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Castration Resistant Prostate Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 13,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07223034",
          "briefTitle": "A Study of 177Lu-PSMA-617 in People With Gliomas"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-10-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Glioma", "Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4)", "Glioblastoma, IDH-wildtype", "Diffuse Midline Glioma, H3 K27-Altered", "Diffuse Hemispheric Glioma, H3 G34-mutant", "Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00990652",
          "briefTitle": "Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-05"
          },
          "completionDateStruct": {
            "date": "2012-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Brain and Central Nervous System Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01966003",
          "briefTitle": "Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-11-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2015-07-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-small Cell Lung Cancer Metastatic"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 642,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04575961",
          "briefTitle": "Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-02-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-03-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Ovarian Cancer", "Low Grade Serous Carcinoma", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 33,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06252870",
          "briefTitle": "Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-07-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-07-18",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Graft Versus Host Disease", "Hematologic Malignancy"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 82,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01939483",
          "briefTitle": "A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-12"
          },
          "completionDateStruct": {
            "date": "2018-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Central Nervous System Metastases", "Male Breast Cancer", "Recurrent Breast Cancer", "Stage IV Breast Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02999854",
          "briefTitle": "Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-11-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-12-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Myelodysplastic Syndrome"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 63,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02707666",
          "briefTitle": "A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-02-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-04-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pleural Mesothelioma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 7,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03325166",
          "briefTitle": "Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-11-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-03-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Lung Carcinoma Metastatic in the Brain", "Stage IV Lung Non-Small Cell Cancer AJCC v7"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 2,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02599402",
          "briefTitle": "Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-12-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-02-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 533,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02989857",
          "briefTitle": "Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-02-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-05-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Cholangiocarcinoma", "Metastatic Cholangiocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 187,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01471353",
          "briefTitle": "Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-11"
          },
          "completionDateStruct": {
            "date": "2017-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Cancer Metastatic"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 43,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05770037",
          "briefTitle": "DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-12-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Haematological Malignancy", "Malignant Neoplasm", "Lymphoproliferative Disorders", "Neoplasms by Histologic Type", "Neoplasms by Site", "Cancer", "Anaplastic Large Cell Lymphoma", "Lymphoma", "Renal Cell Carcinoma", "Neuroblastoma", "Solid Tumour"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03520075",
          "briefTitle": "Study of ASTX029 in Subjects With Advanced Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-05-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-03-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Solid Tumor, Adult"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 192,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04033107",
          "briefTitle": "High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-07-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Hepatocellular Cancer", "Pancreatic Cancer", "Gastric Cancer", "Colorectal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04220892",
          "briefTitle": "Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-07-08",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2020-07-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "High Grade Glioma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04478695",
          "briefTitle": "Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-09-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-10-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Relapsed or Refractory Acute Myeloid Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06357377",
          "briefTitle": "A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Pediatric Tumor of CNS", "Pediatric Tumor of Brain", "Diffuse Midline Glioma, H3 K27M-Mutant", "Pediatric Tumor of Brain Stem", "Pineocytoma", "Choroid Plexus Carcinoma, Childhood", "Spinal Cord Tumor", "High Grade Glioma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 12,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "5 Years",
          "maximumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02076477",
          "briefTitle": "The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancerï¼ˆNSCLCï¼‰"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-01"
          },
          "completionDateStruct": {
            "date": "2020-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Oligo-metastatic Stage IV Non-small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 420,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00429572",
          "briefTitle": "Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "1998-01"
          },
          "completionDateStruct": {
            "date": "2008-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 19,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "60 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00823719",
          "briefTitle": "Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-05"
          },
          "completionDateStruct": {
            "date": "2011-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma, Large-Cell, Diffuse"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 61,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01797965",
          "briefTitle": "Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-02-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-09-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Relapsing-Remitting Multiple Sclerosis", "Multiple Sclerosis"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1501,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03884192",
          "briefTitle": "Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-12-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Carcinoma, Non-Small Cell Lung"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 162,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05078671",
          "briefTitle": "Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-12-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 160,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05810792",
          "briefTitle": "Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-04-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-04-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Pancreatic Cancer", "Surgery", "Metastasis", "Immunosuppression"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02467907",
          "briefTitle": "Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-07-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-01-15",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Cervical Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 152,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01264432",
          "briefTitle": "Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-11-15",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Adult Solid Neoplasm", "Peritoneal Carcinomatosis", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 34,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05167851",
          "briefTitle": "The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-12",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 68,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01209702",
          "briefTitle": "A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-09"
          },
          "completionDateStruct": {
            "date": "2011-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Spondylitis, Ankylosing"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 306,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03399539",
          "briefTitle": "Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-05-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-02-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Plasma Cell Myeloma", "T(11;14)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 8,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03263767",
          "briefTitle": "Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-01-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-06-21",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Graft Versus Host Disease"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 47,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02446600",
          "briefTitle": "Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-03-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-08-23",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Tumor", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Tumor", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Ovarian Endometrioid Adenocarcinoma", "Recurrent Primary Peritoneal Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 579,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07022834",
          "briefTitle": "Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-06-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-06-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Langerhans Cell Histiocytosis (LCH)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "0 Years",
          "maximumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03811002",
          "briefTitle": "Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-07-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-02-21",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Limited Stage Lung Small Cell Carcinoma", "Stage I Lung Cancer AJCC v8", "Stage II Lung Cancer AJCC v8", "Stage III Lung Cancer AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 544,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03558139",
          "briefTitle": "Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-05-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-12-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Ovarian Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 34,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00192075",
          "briefTitle": "A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2003-06"
          },
          "completionDateStruct": {
            "date": "2007-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 84,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02359565",
          "briefTitle": "Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-06-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-21",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Constitutional Mismatch Repair Deficiency Syndrome", "Lynch Syndrome", "Malignant Glioma", "Recurrent Brain Neoplasm", "Recurrent Childhood Ependymoma", "Recurrent Diffuse Intrinsic Pontine Glioma", "Recurrent Medulloblastoma", "Refractory Brain Neoplasm", "Refractory Diffuse Intrinsic Pontine Glioma", "Refractory Ependymoma", "Refractory Medulloblastoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 110,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "1 Year",
          "maximumAge": "30 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00684645",
          "briefTitle": "Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENTÂ®"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-06"
          },
          "completionDateStruct": {
            "date": "2011-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Renal Cell Carcinoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 186,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00832637",
          "briefTitle": "Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-08"
          },
          "completionDateStruct": {
            "date": "2017-03-15",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Hepatocellular Carcinoma", "Cholangiocellular Carcinoma", "Cholangiocarcinoma of the Extrahepatic Bile Duct", "Bile Duct Cancer", "Periampullary Adenocarcinoma", "Gallbladder Cancer", "Extrahepatic Bile Duct Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 33,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01286272",
          "briefTitle": "Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-04-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-09-02",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Ann Arbor Stage III Grade 1 Follicular Lymphoma", "Ann Arbor Stage III Grade 2 Follicular Lymphoma", "Ann Arbor Stage III Grade 3 Follicular Lymphoma", "Ann Arbor Stage IV Grade 1 Follicular Lymphoma", "Ann Arbor Stage IV Grade 2 Follicular Lymphoma", "Ann Arbor Stage IV Grade 3 Follicular Lymphoma", "Grade 3a Follicular Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 135,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03310957",
          "briefTitle": "Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-02-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-09-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Triple Negative Breast Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 185,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00458601",
          "briefTitle": "Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-08"
          },
          "completionDateStruct": {
            "date": "2016-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Malignant Glioma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 82,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01496807",
          "briefTitle": "Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-02-17"
          },
          "completionDateStruct": {
            "date": "2016-08-29",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 31,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "16 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07309211",
          "briefTitle": "Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-07-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "SCLC, Limited Stage"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01719744",
          "briefTitle": "Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-01"
          },
          "completionDateStruct": {
            "date": "2016-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced", "Metastatic", "Soft Tissue Sarcoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06555744",
          "briefTitle": "A Study of ZW191 in Participants With Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-10-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Solid Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 145,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01662102",
          "briefTitle": "Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-12-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2013-03-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Follicular Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06339619",
          "briefTitle": "Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-03-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-09-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 32,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03203473",
          "briefTitle": "Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-10-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-28",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Renal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 85,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02502266",
          "briefTitle": "Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-05-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-07-16",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 582,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06185751",
          "briefTitle": "Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-08-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2040-08-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05642572",
          "briefTitle": "Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-05-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-05-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 66,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05078775",
          "briefTitle": "Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-12-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-07-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Metastatic Pancreatic Adenocarcinoma", "Locally Advanced Unresectable Pancreatic Adenocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 39,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06832865",
          "briefTitle": "ELISA in Relapsed/Refractory MM"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-08-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Relapsed Refractory Multiple Myeloma (RRMM)", "Relapsed Refractory Multiple Myeloma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01654965",
          "briefTitle": "Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-07-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-03-29",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Adult Solid Neoplasm"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 17,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03595592",
          "briefTitle": "Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-09-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-03-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Invasive Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 650,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02488759",
          "briefTitle": "An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-10-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-10-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Various Advanced Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 578,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03816683",
          "briefTitle": "A Disease Registry of Patients With Mantle Cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-04-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-03-18",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Mantle Cell Lymphoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 227,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "130 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00112294",
          "briefTitle": "Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2004-12"
          },
          "completionDateStruct": {
            "date": "2008-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-Small-Cell Lung Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 755,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06692556",
          "briefTitle": "Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-12",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Cutaneous Squamous Cell Carcinoma (CSCC)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 266,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06388902",
          "briefTitle": "A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-02-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Solid Malignancies"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 120,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01399372",
          "briefTitle": "Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-09"
          },
          "completionDateStruct": {
            "date": "2022-05-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Chemotherapeutic Agent Toxicity", "Cognitive/Functional Effects", "Lymphoma", "Neurotoxicity", "Radiation Toxicity"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 91,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      }
    ],
    "protocolSection.1": [
      {
        "identificationModule": {
          "nctId": "NCT02713373",
          "briefTitle": "Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-08-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-07-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Colorectal Carcinoma", "Stage IVA Colorectal Cancer", "Stage IVB Colorectal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00614822",
          "briefTitle": "Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-11"
          },
          "completionDateStruct": {
            "date": "2016-08-22",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04921995",
          "briefTitle": "Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-04-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Nasopharyngeal Carcinoma", "Unresectable Nasopharyngeal Carcinoma", "Chemotherapy Effect", "Immunotherapy", "Stereotactic Body Radiation Therapy (SBRT)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "15 Years",
          "maximumAge": "90 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04739202",
          "briefTitle": "Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-03-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-10-26",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Gastric Adenocarcinoma", "Metastatic Gastric Cancer", "Metastatic Adenocarcinoma", "Advanced Gastric Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02588612",
          "briefTitle": "Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-02-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-08-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04231981",
          "briefTitle": "Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-04-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-08-26",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Penile Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02427841",
          "briefTitle": "Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-01-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-12-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Pancreatic Adenocarcinoma", "Resectable Pancreatic Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00949702",
          "briefTitle": "A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-09-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2014-06-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Malignant Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 132,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03207867",
          "briefTitle": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-08-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-02-14",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["NSCLC, Non Small Cell Lung Cancer", "RCC, Renal Cell Cancer", "Pancreatic Cancer", "Urothelial Cancer", "Head and Neck Cancer", "DLBCL, Diffused Large B Cell Lymphoma", "MSS, Microsatellite Stable Colon Cancer", "TNBC, Triple Negative Breast Cancer", "Melanoma", "mCRPC, Metastatic Castration Resistant Prostate Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 315,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03323151",
          "briefTitle": "A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-08-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-09-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Mantle-Cell Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 43,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06087653",
          "briefTitle": "Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-10-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-03-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 24,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01653912",
          "briefTitle": "Dose-finding Study in Platinum-Resistant Ovarian Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-11"
          },
          "completionDateStruct": {
            "date": "2015-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent Platinum-resistant Ovarian Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 59,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05983094",
          "briefTitle": "Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-09-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-09-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Breast Cancer", "Neoadjuvant Therapy"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 181,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06462001",
          "briefTitle": "BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-12-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Transitional Cell Carcinoma", "Transurethral Resection"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 500,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01808820",
          "briefTitle": "Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-08-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-07-16",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Malignant Glioma", "Glioblastoma Multiforme", "Anaplastic Astrocytoma", "High Grade Glioma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "13 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06255379",
          "briefTitle": "Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-05-06",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-03-21",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Metastasis Colorectal Cancer", "Colon Cancer", "Rectal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 52,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05041062",
          "briefTitle": "A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-12-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-04-13",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Mesothelioma", "Peritoneal Mesothelioma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 2,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03255096",
          "briefTitle": "A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-08-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-07-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Diffuse Large B-cell Lymphoma", "High-Grade B-cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 39,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03496662",
          "briefTitle": "BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-08-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-07-25",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Ductal Adenocarcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02602327",
          "briefTitle": "Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-01-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-08-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Colon Cancer", "Rectal Cancer", "Liver Metastases"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 21,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07126561",
          "briefTitle": "Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-11-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-11-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 43,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06415669",
          "briefTitle": "A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-05-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-05-19",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Gastric/Gastroesophageal Junction Adenocarcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06815003",
          "briefTitle": "Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-04-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-10-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Graft Versus Host Disease", "Myelodysplastic Syndrome", "Myeloproliferative Neoplasm"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 35,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06243003",
          "briefTitle": "WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-01-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["SCLC,Extensive Stage", "Brain Metastases"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 56,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06907342",
          "briefTitle": "Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-05-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2040-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Tumor, Colorectal", "Organoids", "Tumoroid", "Metastatic Colorectal Cancer", "Core Needle Biopsy", "First-line Treatment"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 148,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05815173",
          "briefTitle": "Ladarixin With Sotorasib in Advanced NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-08-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "100 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05116683",
          "briefTitle": "ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-01-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-10-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Leiomyosarcoma", "Liposarcoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 4,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04037254",
          "briefTitle": "Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-10-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-09-26",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Prostate Adenocarcinoma", "Stage IIC Prostate Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8", "Stage IIIA Prostate Cancer AJCC v8", "Stage IIIB Prostate Cancer AJCC v8", "Stage IIIC Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 22,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06321289",
          "briefTitle": "Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-03-20",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-03-20",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non-hodgkin Lymphoma,B Cell"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04676997",
          "briefTitle": "Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-05-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-02-28",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Triple Negative Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05438459",
          "briefTitle": "GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-06-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-03-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Gastric Cancer", "Pancreatic Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 130,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02207062",
          "briefTitle": "Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-10"
          },
          "completionDateStruct": {
            "date": "2023-11-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Transformed B-Cell Non-Hodgkin Lymphoma", "Refractory Transformed B-Cell Non-Hodgkin Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01501370",
          "briefTitle": "Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-01"
          },
          "completionDateStruct": {
            "date": "2012-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00107718",
          "briefTitle": "Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2004-11-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2006-05-19",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 64,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05617313",
          "briefTitle": "Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-02-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-06-26",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Non Small Cell Lung Cancer", "Metastatic NSCLC", "Recurrent Non Small Cell Lung Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 21,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02569320",
          "briefTitle": "HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-05-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-03-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent Plasma Cell Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 9,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02928224",
          "briefTitle": "Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-10-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-11-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "BRAF V600E-mutant Metastatic Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 702,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02215980",
          "briefTitle": "STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-07-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 210,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05746897",
          "briefTitle": "A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-04-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-09-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Ovarian Cancer", "Melanoma", "Triple Negative Breast Cancer", "Colorectal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 38,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05904080",
          "briefTitle": "Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-02-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-06-16",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Metastatic Nasopharyngeal Carcinoma", "Recurrent Nasopharyngeal Carcinoma", "Stage IV Nasopharyngeal Carcinoma AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05418088",
          "briefTitle": "Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-06-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-07-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Acute Lymphoblastic Leukemia", "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent B-Cell Prolymphocytic Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent High Grade B-Cell Lymphoma", "Recurrent Indolent Non-Hodgkin Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Transformed Chronic Lymphocytic Leukemia", "Refractory Acute Lymphoblastic Leukemia", "Refractory B Acute Lymphoblastic Leukemia", "Refractory B-Cell Prolymphocytic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory High Grade B-Cell Lymphoma", "Refractory Indolent Non-Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Transformed Chronic Lymphocytic Leukemia", "Refactory Childhood Acute Lymphoblastic Leukemia", "Refractory Childhood Non-Hodgkin Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 54,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "2 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00376961",
          "briefTitle": "S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-08"
          },
          "completionDateStruct": {
            "date": "2017-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 68,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02719574",
          "briefTitle": "Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-04-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-01-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Acute Myelogenous Leukemia", "Myelodysplastic Syndrome"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 336,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03441360",
          "briefTitle": "Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-04-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-01-21",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Relapsed/Refractory Rhabdomyosarcoma", "Non-rhabdomyosarcoma Soft Tissue Sarcoma", "Ewing Sarcoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 23,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Months",
          "maximumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01915524",
          "briefTitle": "Trial of RNActiveÂ®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-04"
          },
          "completionDateStruct": {
            "date": "2016-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-Small Cell Lung Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 26,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01763788",
          "briefTitle": "A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-05-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-10-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Squamous Non-small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 192,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05057013",
          "briefTitle": "A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-11-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Bladder Cancer", "Triple Negative Breast Cancer", "Castration-resistant Prostate Cancer", "Cervical Cancer", "RAS Wild Type Colorectal Cancer", "Endometrial Cancer", "Gastric Cancer", "Hepatocellular Carcinoma (HCC)", "Melanoma", "Non-small Cell Lung Cancer (NSCLC)", "Oesophageal Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Squamous Cell Cancer of the Head and Neck"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 81,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "16 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04237623",
          "briefTitle": "GM-CSF With Post-Transplant Cyclophosphamide"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-05-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-09-18",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Transplant-Related Hematologic Malignancy"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 38,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "78 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03250676",
          "briefTitle": "Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-08-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-10-26",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Breast Neoplasms", "Breast Cancer", "Estrogen-receptor Positive Breast Cancer", "Cancer, Breast", "Breast Cancer Female", "Breast Adenocarcinoma", "Estrogen Receptor Positive Tumor", "ER Positive"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 151,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06484491",
          "briefTitle": "IMPT Dose Escalation for NSCLC (HyDose)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-09-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-10-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Carcinoma, Non-Small-Cell Lung"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 87,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03289910",
          "briefTitle": "Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-09-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-19",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Atypical Chronic Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Essential Thrombocythemia", "Myelodysplastic/Myeloproliferative Neoplasm", "Myelofibrosis", "Polycythemia Vera", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02345460",
          "briefTitle": "Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-09"
          },
          "completionDateStruct": {
            "date": "2016-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Pancreatic Adenocarcinoma", "Poorly Differentiated Malignant Neoplasm", "Resectable Pancreatic Cancer", "Stage IA Pancreatic Cancer", "Stage IB Pancreatic Cancer", "Stage IIA Pancreatic Cancer", "Stage IIB Pancreatic Cancer", "Stage III Pancreatic Cancer", "Undifferentiated Pancreatic Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07308379",
          "briefTitle": "Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-02",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["SCLC, Extensive Stage", "Toripalimab"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 1200,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01421927",
          "briefTitle": "Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-08"
          },
          "completionDateStruct": {
            "date": "2014-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 13,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01449461",
          "briefTitle": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-09-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-02-18",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Lymphoma, Large-Cell, Anaplastic", "Carcinoma, Non-Small-Cell Lung"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 137,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05136196",
          "briefTitle": "BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-12-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-01-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Locally Recurrent Head and Neck Squamous Cell Carcinoma", "Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Locally Recurrent Laryngeal Squamous Cell Carcinoma", "Locally Recurrent Oral Cavity Squamous Cell Carcinoma", "Locally Recurrent Oropharyngeal Squamous Cell Carcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Hypopharyngeal Squamous Cell Carcinoma", "Metastatic Laryngeal Squamous Cell Carcinoma", "Metastatic Melanoma", "Metastatic Oral Cavity Squamous Cell Carcinoma", "Metastatic Oropharyngeal Squamous Cell Carcinoma", "Recurrent Melanoma", "Stage III Hypopharyngeal Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Lip and Oral Cavity Cancer AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IV Hypopharyngeal Carcinoma AJCC v8", "Stage IV Laryngeal Cancer AJCC v8", "Stage IV Lip and Oral Cavity Cancer AJCC v8", "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Unresectable Melanoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 150,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07226986",
          "briefTitle": "A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12-16",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-08-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 123,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05917405",
          "briefTitle": "Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-09-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-09-14",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Myeloid Leukemia in Remission"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 302,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00528866",
          "briefTitle": "Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-05-14",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Prostate Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 80,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04795661",
          "briefTitle": "Immunotherapy in MSI/dMMR Tumors in Perioperative Setting."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-10-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Localized Resectable Tumor", "MSI/dMMR"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 240,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01952769",
          "briefTitle": "Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-02"
          },
          "completionDateStruct": {
            "date": "2019-04",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "DIPG"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "3 Years",
          "maximumAge": "21 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04534283",
          "briefTitle": "A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-10-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-08-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Cancer", "Cancer Metastatic", "BRAF V600E", "MEK1 Gene Mutation", "MEK2 Gene Mutation", "ERK Mutation", "RAF1 Gene Mutation"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 16,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06462105",
          "briefTitle": "Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-07-05",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03161756",
          "briefTitle": "Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-12-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Melanoma Stage Iv", "Melanoma Stage Iii", "Melanoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 72,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02119663",
          "briefTitle": "A Study of Ruxolitinib in Pancreatic Cancer Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 86,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00889187",
          "briefTitle": "Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2011-12-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06908993",
          "briefTitle": "Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-07-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Non Small Cell Lung Cancer", "MET Exon 14 Mutation"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 133,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01215136",
          "briefTitle": "First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-12"
          },
          "completionDateStruct": {
            "date": "2018-04-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Transitional Cell Carcinoma", "Bladder Carcinoma", "Urothelial Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 36,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04253964",
          "briefTitle": "Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-07-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-03",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Nonsmall Cell Lung Cancer", "Performance Status"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 80,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01168232",
          "briefTitle": "Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-09-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2013-11-26",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Uterine Corpus Sarcoma", "Uterine Carcinosarcoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 42,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06333314",
          "briefTitle": "Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-07-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Pancreatic Adenocarcinoma", "Ampulla of Vater Carcinoma", "Adrenocortical Carcinoma", "Neuroendocrine Carcinoma", "Soft Tissue Sarcoma", "Small Bowel Adenocarcinoma", "Duodenum Adenocarcinoma", "Gastric Adenocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 120,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01156584",
          "briefTitle": "A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-07"
          },
          "completionDateStruct": {
            "date": "2016-08-18",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Glioblastoma", "Anaplastic Astrocytoma", "Anaplastic Oligodendroglioma", "Anaplastic Oligoastrocytoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 54,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00234052",
          "briefTitle": "Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2005-07-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2011-11-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 51,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06545955",
          "briefTitle": "A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-10-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non-muscle Invasive Bladder Cancer With Carcinoma in Situ"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 250,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03181126",
          "briefTitle": "A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-11-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-11-14",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Lymphoblastic Leukemia (ALL)", "Lymphoblastic Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 69,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "4 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03229278",
          "briefTitle": "Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-10-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-10-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Lymphoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Cancer", "Recurrent Bladder Carcinoma", "Recurrent Classical Hodgkin Lymphoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Renal Cell Carcinoma", "Stage III Bladder Cancer", "Stage III Lymphoma", "Stage III Non-Small Cell Lung Cancer AJCC v7", "Stage III Renal Cell Cancer", "Stage III Skin Melanoma", "Stage IIIA Non-Small Cell Lung Cancer AJCC v7", "Stage IIIA Skin Melanoma", "Stage IIIB Non-Small Cell Lung Cancer AJCC v7", "Stage IIIB Skin Melanoma", "Stage IIIC Skin Melanoma", "Stage IV Bladder Cancer", "Stage IV Lymphoma", "Stage IV Non-Small Cell Lung Cancer AJCC v7", "Stage IV Renal Cell Cancer", "Stage IV Skin Melanoma", "Stage IVA Bladder Cancer", "Stage IVB Bladder Cancer", "Unresectable Head and Neck Squamous Cell Carcinoma", "Unresectable Solid Neoplasm"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 14,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05281471",
          "briefTitle": "Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-08-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Platinum-resistant Ovarian Cancer", "Platinum-refractory Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer", "High-grade Serous Ovarian Cancer", "Endometrioid Ovarian Cancer", "Ovarian Clear Cell Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 186,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03507244",
          "briefTitle": "Concurrent Intrathecal-pemetrexed and Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-04-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-07-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Leptomeningeal Metastasis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 34,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03334487",
          "briefTitle": "Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-03-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-12-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05479578",
          "briefTitle": "Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-06-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-05-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Adenocarcinoma", "Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) V8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 7,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02555267",
          "briefTitle": "Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma, Large B-cell, Diffuse"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 148,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06878664",
          "briefTitle": "Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-06-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 166,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00316849",
          "briefTitle": "Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-05"
          },
          "completionDateStruct": {}
        },
        "conditionsModule": {
          "conditions": ["Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 56,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06050512",
          "briefTitle": "Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-10-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Relapsed and Refractory Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05000892",
          "briefTitle": "Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-12-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-10-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Salivary Gland Malignant Neoplasms", "Salivary Gland Tumors"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 15,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03929211",
          "briefTitle": "CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-05",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Myelodysplastic Syndromes", "Progressive Disease"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01415011",
          "briefTitle": "Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-12"
          },
          "completionDateStruct": {
            "date": "2018-11-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Carcinoma, Non-Small-Cell Lung"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 39,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05364645",
          "briefTitle": "Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-07-25",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-05-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Lung Non-Small Cell Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03779230",
          "briefTitle": "Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-05-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-06-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Glioma of Brain"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "90 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06747728",
          "briefTitle": "Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-03-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Brain Glioma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03449030",
          "briefTitle": "A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-04-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-02-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 31,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02020707",
          "briefTitle": "Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-02-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-07-18",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Cervical Adenocarcinoma", "Cervical Adenosarcoma", "Cervical Adenosquamous Carcinoma", "Cervical Carcinosarcoma", "Cervical Squamous Cell Carcinoma", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Endometrial Adenosquamous Carcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Endometrioid Adenocarcinoma", "Endometrial Mixed Cell Adenocarcinoma", "Endometrial Mucinous Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Undifferentiated Carcinoma", "Fallopian Tube Adenocarcinoma", "Fallopian Tube Carcinosarcoma", "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Squamous Cell Carcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Malignant Female Reproductive System Neoplasm", "Malignant Ovarian Clear Cell Tumor", "Malignant Ovarian Endometrioid Tumor", "Malignant Ovarian Epithelial Tumor", "Malignant Ovarian Mucinous Tumor", "Malignant Peritoneal Neoplasm", "Malignant Solid Neoplasm", "Ovarian Carcinosarcoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Platinum-Sensitive Ovarian Carcinoma", "Primary Peritoneal Carcinosarcoma", "Primary Peritoneal Clear Cell Adenocarcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Primary Peritoneal Transitional Cell Carcinoma", "Primary Peritoneal Undifferentiated Carcinoma", "Unresectable Melanoma", "Uterine Corpus Carcinosarcoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 43,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01543698",
          "briefTitle": "A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-05-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-03-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Solid Tumors Harboring a BRAF V600 Mutation"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 189,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02291614",
          "briefTitle": "A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-11-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-01-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "GI Adenocarcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02101775",
          "briefTitle": "Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-07-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-02-20",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Ovarian Brenner Tumor", "Ovarian Carcinosarcoma", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Cystadenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Cystadenocarcinoma", "Ovarian Serous Surface Papillary Adenocarcinoma", "Ovarian Undifferentiated Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 124,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07166419",
          "briefTitle": "Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-02-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive", "Recurrent Indolent Non-Hodgkin Lymphoma", "Recurrent Lymphoblastic Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Transformed Chronic Lymphocytic Leukemia", "Refractory Acute Lymphoblastic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive", "Refractory Indolent Non-Hodgkin Lymphoma", "Refractory Lymphoblastic Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Transformed Chronic Lymphocytic Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 24,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01970865",
          "briefTitle": "A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-01-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-05-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 364,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05764044",
          "briefTitle": "Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-03-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Cervical Cancer", "Cervix Cancer", "Cervix Neoplasm"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 365,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06971744",
          "briefTitle": "Autophagy Maintenance (AUTOMAIN)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-06-18",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Ovarian Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 38,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06733038",
          "briefTitle": "FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-11-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-04-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 238,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      }
    ],
    "protocolSection.2": [
      {
        "identificationModule": {
          "nctId": "NCT05498155",
          "briefTitle": "Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-11-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "130 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06159478",
          "briefTitle": "Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-03-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-09-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Low-grade Glioma", "Pancreatic Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 32,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03118492",
          "briefTitle": "Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-05-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-05-26",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Secondary Myelofibrosis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 22,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00693992",
          "briefTitle": "Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-06-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2015-05-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Stage IIIB Lung Non-Small Cell Cancer AJCC v7", "Stage IV Non-Small Cell Lung Cancer AJCC v7"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 210,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05176470",
          "briefTitle": "Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-07-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Locally Advanced Melanoma", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Stage IV Melanoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 2,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06662877",
          "briefTitle": "Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-11-25",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-09-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Biliary Tract Cancer", "Second Line Treatment", "Chemotherapy", "Tyrosine Kinase Inhibitor"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 206,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06697327",
          "briefTitle": "Daunorubicin + Cytarabine + Venetoclax in de Novo AML"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-02-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-08-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Leukemia, Myeloid, Acute", "Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 94,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "59 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04093466",
          "briefTitle": "A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-04-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Solid Tumor"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 126,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01352429",
          "briefTitle": "Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-08"
          },
          "completionDateStruct": {
            "date": "2026-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Prostate Adenocarcinoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 303,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06657027",
          "briefTitle": "Artificial Intelligence-Guided Radiotherapy Planning for Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-01-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Glioblastoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "15 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00372905",
          "briefTitle": "Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-07-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2013-07-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00780494",
          "briefTitle": "Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-02"
          },
          "completionDateStruct": {
            "date": "2017-12-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Stomach Cancer", "Gastric (Stomach) Cancer", "Neoplasm of Cardioesophageal Junction", "Gastrointestinal Stromal Tumor (GIST)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 35,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02837029",
          "briefTitle": "Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-07"
          },
          "completionDateStruct": {
            "date": "2020-11-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Stage IIIA Hepatocellular Carcinoma", "Stage IIIB Hepatocellular Carcinoma", "Stage IIIC Hepatocellular Carcinoma", "Stage IVA Hepatocellular Carcinoma", "Stage IVB Hepatocellular Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 27,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02583269",
          "briefTitle": "Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-04-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Malignant Neoplasm", "Metastatic Malignant Neoplasm", "Unresectable Malignant Neoplasm"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 24,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05456269",
          "briefTitle": "A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-07-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-08-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia", "Higher Risk Myelodysplastic Syndrome", "Chronic Myelomonocytic Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06313554",
          "briefTitle": "Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-05-20",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-05-20",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Intrahepatic Cholangiocarcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 63,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03070366",
          "briefTitle": "Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-09-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Head and Neck Squamous Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 78,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "77 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01208051",
          "briefTitle": "Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-09-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-02-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Refractory Differentiated Thyroid Gland Carcinoma", "Refractory Thyroid Gland Follicular Carcinoma", "Refractory Thyroid Gland Hurthle Cell Carcinoma", "Refractory Thyroid Gland Papillary Carcinoma", "Unresectable Thyroid Gland Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 127,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01943851",
          "briefTitle": "A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-05-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-04-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 111,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06016842",
          "briefTitle": "A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-08-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-05-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Primary Biliary Cholangitis (PBC)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 276,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00331773",
          "briefTitle": "Radiation Therapy in Treating Patients With Stage II Prostate Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-12-22",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Prostate Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1116,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06364956",
          "briefTitle": "Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-05-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Bladder Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 36,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00504257",
          "briefTitle": "Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-03"
          },
          "completionDateStruct": {
            "date": "2012-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Fallopian Tube Cancer", "Ovarian Cancer", "Malignant Tumor of Peritoneum"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05479994",
          "briefTitle": "Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-10-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-08-25",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Leukemia", "Lymphoma", "Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Small Lymphocytic Lymphoma", "Relapsed Chronic Lymphocytic Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 100,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06572631",
          "briefTitle": "Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-06-07",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-12-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Acute Myeloid Leukemia", "Recurrent Myelodysplastic Syndrome", "Refractory Acute Myeloid Leukemia", "Refractory Myelodysplastic Syndrome"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06447727",
          "briefTitle": "Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-05-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-11-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Cancer Metastatic"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03879694",
          "briefTitle": "Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-06-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-03-14",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Lung Atypical Carcinoid Tumor", "Lung Typical Carcinoid Tumor", "Metastatic Pancreatic Neuroendocrine Tumor"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 19,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03418324",
          "briefTitle": "Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-03-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-11-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Prostate Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 11,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05057702",
          "briefTitle": "Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-02-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-01-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Medulloblastoma", "Medulloblastoma, Childhood", "Medulloblastoma Recurrent", "Ependymoma", "Ependymoma Malignant", "Ependymoma of Brain"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 74,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Months",
          "maximumAge": "39 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00001379",
          "briefTitle": "Treatment and Natural History Study of Lymphomatoid Granulomatosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "1995-05-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-01-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Lymphomatoid Granulomatosis", "Granulomatosis, Lymphomatoid", "Non-Hodgkins Lymphoma", "Lymphoproliferative Disorder"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 94,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04417062",
          "briefTitle": "Olaparib With Ceralasertib in Recurrent Osteosarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-11-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Osteosarcoma", "Osteosarcoma Recurrent"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 63,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years",
          "maximumAge": "40 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00098527",
          "briefTitle": "FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2004-10"
          },
          "completionDateStruct": {}
        },
        "conditionsModule": {
          "conditions": ["Adenocarcinoma of the Esophagus", "Adenocarcinoma of the Stomach", "Recurrent Esophageal Cancer", "Recurrent Gastric Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04564027",
          "briefTitle": "A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-12-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-02-18",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Solid Tumours"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 54,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "130 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03042169",
          "briefTitle": "Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-08-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-08-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Gastric Adenocarcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 6,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00560794",
          "briefTitle": "Phase II Study of the BiTEÂ® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-01"
          },
          "completionDateStruct": {
            "date": "2014-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Lymphoblastic Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 21,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01287520",
          "briefTitle": "A Study of LY2090314 in Patients With Advanced or Metastatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-11"
          },
          "completionDateStruct": {
            "date": "2011-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 41,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "25 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03526679",
          "briefTitle": "Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-07-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-10-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Leiomyosarcoma", "Liposarcoma", "Soft Tissue Sarcoma Adult", "Advanced Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03919227",
          "briefTitle": "Measurement of Resistance During UAS Insertion Procedure in RIRS"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-09-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Urolithiasis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 120,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07090954",
          "briefTitle": "A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-08-31",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2030-01-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 32,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01101594",
          "briefTitle": "A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-07"
          },
          "completionDateStruct": {
            "date": "2013-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 17,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03334409",
          "briefTitle": "Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-02-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-03-13",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Clear Cell Renal Cell Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v7", "Unresectable Renal Cell Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 5,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01294306",
          "briefTitle": "MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-02"
          },
          "completionDateStruct": {
            "date": "2015-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Adenosquamous Lung Carcinoma", "Bronchioloalveolar Carcinoma", "Large Cell Lung Carcinoma", "Lung Adenocarcinoma", "Recurrent Non-Small Cell Lung Carcinoma", "Squamous Cell Lung Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 80,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06259058",
          "briefTitle": "Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-04-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 96,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04462328",
          "briefTitle": "Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-04-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-10-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Primary Central Nervous System Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01981187",
          "briefTitle": "LGX818 for Patients With BRAFV600 Mutated Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-01-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2015-10-13",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Solid Tumor", "Hematologic Malignancies"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 12,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07112833",
          "briefTitle": "A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-08-10",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 36,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03200847",
          "briefTitle": "Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-10-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-10-19",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Stage IV Melanoma", "Stage III Melanoma", "Advanced Melanoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 26,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "100 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05874193",
          "briefTitle": "A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-10",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Relapsed/Refractory Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 33,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02370238",
          "briefTitle": "A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-07-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-03-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 194,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03611985",
          "briefTitle": "Phase I/IIa Study of Pharmacokinetics and Safety of Epidiferphaneâ„¢ and Taxanes in Breast Cancer Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-03",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2023-03",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00706238",
          "briefTitle": "MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-09-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2011-01-19",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 5,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03660826",
          "briefTitle": "Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-09-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-01-24",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Endometrial Adenocarcinoma", "Endometrial Mixed Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Undifferentiated Carcinoma", "Endometrioid Adenocarcinoma", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 288,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07237399",
          "briefTitle": "Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-01-02",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2031-04-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Oligometastatic Prostate Cancer (OMPC)", "Prostate Cancer (Adenocarcinoma)", "Ablation Techniques"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03246958",
          "briefTitle": "Nivolumab Plus Ipilimumab in Thyroid Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-10-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-07-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Thyroid Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 53,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01943864",
          "briefTitle": "A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-09-19"
          },
          "completionDateStruct": {
            "date": "2016-02-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01870726",
          "briefTitle": "Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-01-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-12-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 43,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04899921",
          "briefTitle": "Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-06-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-05-29",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Melanoma", "Metastatic Melanoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03274804",
          "briefTitle": "Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-04-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-03-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Metastatic Colorectal Cancer", "MSS"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00559949",
          "briefTitle": "Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-12"
          },
          "completionDateStruct": {
            "date": "2016-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Thyroid Gland Carcinoma", "Stage I Thyroid Gland Papillary Carcinoma", "Stage II Thyroid Gland Papillary Carcinoma", "Stage III Thyroid Gland Papillary Carcinoma", "Stage IV Thyroid Gland Papillary Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 39,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03361735",
          "briefTitle": "Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-08-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-02-04",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Prostate Adenocarcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02530125",
          "briefTitle": "Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Stage III Diffuse Large B-Cell Lymphoma", "Stage IV Diffuse Large B-Cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 4,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06623110",
          "briefTitle": "Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-01-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "High-Risk Oral Precancerous Disease"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07046780",
          "briefTitle": "A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in the Treatment of Locally Advanced or Metastatic Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-07-30",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Solid Tumor Cancer", "Metastatic Solid Tumors", "Locally Advanced"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 90,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02034110",
          "briefTitle": "Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-03-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-12-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 206,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05627323",
          "briefTitle": "CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-06-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2041-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Glioblastoma Multiforme of Brain"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 42,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00086996",
          "briefTitle": "S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2004-09"
          },
          "completionDateStruct": {
            "date": "2011-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Esophageal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 98,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07036250",
          "briefTitle": "Clinical Study of U32 in Patients With Acute Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-07-03",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Myeloid Leukaemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "2 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01090960",
          "briefTitle": "A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-03"
          },
          "completionDateStruct": {
            "date": "2015-02",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Solid Cancers"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 52,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00107380",
          "briefTitle": "S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2005-11"
          },
          "completionDateStruct": {
            "date": "2015-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 86,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04127435",
          "briefTitle": "High Dose Rate Interstitial Brachytherapy With Three Dimensional Printing Template for Recurrent Gynecologic Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Cervical Cancer"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02834013",
          "briefTitle": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-01-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-05-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acinar Cell Carcinoma", "Adenoid Cystic Carcinoma", "Adrenal Cortical Carcinoma", "Adrenal Gland Pheochromocytoma", "Anal Canal Neuroendocrine Carcinoma", "Anal Canal Undifferentiated Carcinoma", "Angiosarcoma", "Apocrine Neoplasm", "Appendix Mucinous Adenocarcinoma", "Bartholin Gland Transitional Cell Carcinoma", "Basal Cell Carcinoma", "Bladder Adenocarcinoma", "Breast Metaplastic Carcinoma", "Cervical Adenocarcinoma", "Cholangiocarcinoma", "Chordoma", "Colorectal Squamous Cell Carcinoma", "Desmoid Fibromatosis", "Endometrial Transitional Cell Carcinoma", "Endometrioid Adenocarcinoma", "Esophageal Neuroendocrine Carcinoma", "Esophageal Undifferentiated Carcinoma", "Extrahepatic Bile Duct Carcinoma", "Extramammary Paget Disease", "Fallopian Tube Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fibromyxoid Tumor", "Gallbladder Carcinoma", "Gastric Neuroendocrine Carcinoma", "Gastric Squamous Cell Carcinoma", "Gastric Undifferentiated Carcinoma", "Gastrointestinal Stromal Tumor", "Gestational Trophoblastic Tumor", "Giant Cell Carcinoma", "Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type", "Intestinal Neuroendocrine Carcinoma", "Intrahepatic Cholangiocarcinoma", "Lung Neuroendocrine Tumor", "Lung Sarcomatoid Carcinoma", "Major Salivary Gland Carcinoma", "Malignant Neoplasm of Unknown Primary", "Malignant Odontogenic Neoplasm", "Malignant Peripheral Nerve Sheath Tumor", "Malignant Solid Neoplasm", "Malignant Testicular Sex Cord-Stromal Tumor", "Metastatic Pituitary Neuroendocrine Tumor", "Minimally Invasive Lung Adenocarcinoma", "Mixed Mesodermal (Mullerian) Tumor", "Mucinous Adenocarcinoma", "Mucinous Cystadenocarcinoma", "Nasal Cavity Adenocarcinoma", "Nasal Cavity Carcinoma", "Nasopharyngeal Carcinoma", "Nasopharyngeal Low Grade Papillary Adenocarcinoma", "Nasopharyngeal Undifferentiated Carcinoma", "Oral Cavity Carcinoma", "Oropharyngeal Undifferentiated Carcinoma", "Ovarian Adenocarcinoma", "Ovarian Germ Cell Tumor", "Ovarian Mucinous Adenocarcinoma", "Ovarian Squamous Cell Carcinoma", "Ovarian Transitional Cell Carcinoma", "Pancreatic Acinar Cell Carcinoma", "Pancreatic Neuroendocrine Carcinoma", "Paraganglioma", "Paranasal Sinus Adenocarcinoma", "Paranasal Sinus Carcinoma", "Parathyroid Gland Carcinoma", "PEComa", "Penile Squamous Cell Carcinoma", "Peritoneal Mesothelial Neoplasm", "Placental Choriocarcinoma", "Primary Peritoneal High Grade Serous Adenocarcinoma", "Pseudomyxoma Peritonei", "Rare Disorder", "Scrotal Squamous Cell Carcinoma", "Seminal Vesicle Adenocarcinoma", "Seminoma", "Serous Cystadenocarcinoma", "Small Intestinal Adenocarcinoma", "Small Intestinal Squamous Cell Carcinoma", "Spindle Cell Neoplasm", "Teratoma With Somatic-Type Malignancy", "Testicular Non-Seminomatous Germ Cell Tumor", "Thyroid Gland Carcinoma", "Tracheal Carcinoma", "Transitional Cell Carcinoma", "Ureter Adenocarcinoma", "Ureter Squamous Cell Carcinoma", "Urethral Adenocarcinoma", "Urethral Squamous Cell Carcinoma", "Vaginal Adenocarcinoma", "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified", "Vulvar Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 818,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05361720",
          "briefTitle": "Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-12-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-07-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Clear Cell Renal Cell Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 54,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06814496",
          "briefTitle": "Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-09-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-05",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Melanoma", "Medullary Thyroid Cancer", "Sinonasal Undifferentiated Carcinoma", "Esthesioneuroblastoma", "Bladder Cancer", "Testicular Cancer", "Glioblastoma Multiforme", "Cervical Cancer", "Large Cell Neuroendocrine Carcinoma of the Lung", "Non Small Cell Lung Cancer", "Merkel Cell Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06691035",
          "briefTitle": "Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-11-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Breast Cancer Metastatic Breast Cancer", "HER2-negative Breast Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06911008",
          "briefTitle": "MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-11-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-04-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Metastatic Malignant Solid Neoplasm", "Refractory Malignant Solid Neoplasm", "Unresectable Malignant Solid Neoplasm"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 42,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06859008",
          "briefTitle": "Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-02-07",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-01-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3a Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Nodal Marginal Zone Lymphoma", "Recurrent Splenic Marginal Zone Lymphoma", "Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Refractory Grade 1 Follicular Lymphoma", "Refractory Grade 2 Follicular Lymphoma", "Refractory Grade 3a Follicular Lymphoma", "Refractory Mantle Cell Lymphoma", "Refractory Nodal Marginal Zone Lymphoma", "Refractory Splenic Marginal Zone Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 37,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05579340",
          "briefTitle": "Postoperative Exercise Training and Colorectal Cancer Liver Metastasis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-04",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2025-04",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Cancer Metastatic to Liver", "Cancer Colorectal"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 66,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00301418",
          "briefTitle": "Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-03"
          },
          "completionDateStruct": {
            "date": "2014-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Glioblastoma Multiforme", "Anaplastic Astrocytoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 11,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05016882",
          "briefTitle": "Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-08-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-03-14",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-alcoholic Steatohepatitis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 698,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02633059",
          "briefTitle": "Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-12-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-11-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Loss of Chromosome 17p", "Recurrent Plasma Cell Myeloma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 33,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00910091",
          "briefTitle": "The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-08"
          },
          "completionDateStruct": {
            "date": "2013-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Endometrial Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 73,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02181413",
          "briefTitle": "A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-07-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-09-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Multiple Myeloma", "Autologous Stem Cell Transplant"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 656,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00045708",
          "briefTitle": "A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2002-10"
          },
          "completionDateStruct": {
            "date": "2010-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Adult Anaplastic Astrocytoma", "Adult Giant Cell Glioblastoma", "Adult Gliosarcoma", "Recurrent Adult Brain Tumor"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 57,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05378425",
          "briefTitle": "A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-09-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Cancer", "Tumor, Solid", "Advanced Solid Tumor", "Metastatic Cancer", "Locally Advanced Solid Tumor"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 90,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05476796",
          "briefTitle": "Oxaliplatin Â± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-06-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Gastric Adenocarcinoma", "Esophagus Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 118,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02736617",
          "briefTitle": "Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-07-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-06-02",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Mantle Cell Lymphoma", "Refractory Mantle Cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02045017",
          "briefTitle": "Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-02-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-07-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 81,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02411591",
          "briefTitle": "A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-06-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-05-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Carcinoma, Non-Small-Cell Lung", "Neoplasm Metastasis"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 66,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01591135",
          "briefTitle": "A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Esophageal Squamous Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 436,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05432635",
          "briefTitle": "Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-08-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["B-Cell Non-Hodgkin Lymphoma", "Diffuse Large B-Cell Lymphoma", "Mantle Cell Lymphoma", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Transformed Non-Hodgkin Lymphoma", "Transformed Non-Hodgkin Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 15,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02669017",
          "briefTitle": "Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-03"
          },
          "completionDateStruct": {
            "date": "2019-02-21",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Non-Hodgkin Lymphoma", "Burkitt's Lymphoma", "Chronic Lymphocytic Leukemia", "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Follicular", "Lymphoma, Mantle-Cell", "Lymphoma, Marginal Zone", "Waldenstrom Macroglobulinemia", "Primary Mediastinal B-cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 183,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04882917",
          "briefTitle": "First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-05-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-03-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Solid Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 22,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05076513",
          "briefTitle": "Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-10-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Glioblastoma", "Glioblastoma Multiforme", "Glioma", "GBM", "Glioma, Malignant", "Glioblastoma Multiforme of Brain"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 42,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04163289",
          "briefTitle": "Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-01-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Renal Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07276360",
          "briefTitle": "Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-01-03",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-01-02",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Cervical Cancer", "Cervix Cancer", "Cervical Adenocarcinoma", "Cervical Small Cell Carcinoma", "Cervical Adenosquamous Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 278,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00079417",
          "briefTitle": "Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2005-12-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-03-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Intraocular Retinoblastoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 28,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "5 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04677413",
          "briefTitle": "Ultra-fractionated Radiotherapy for Rectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-06-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Rectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 27,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04234113",
          "briefTitle": "Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-06-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-11-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Thyroid Cancer", "Renal Cell Carcinoma", "Non Small Cell Lung Cancer", "Small-cell Lung Cancer", "Bladder Cancer", "Melanoma", "Merkel Cell Carcinoma", "Skin Squamous Cell Carcinoma", "Microsatellite Instability High", "Triple Negative Breast Cancer", "Mesothelioma", "Thymic Cancer", "Cervical Cancer", "Biliary Tract Cancer", "Hepatocellular Carcinoma", "Ovarian Cancer", "Gastric Cancer", "Head and Neck Squamous Cell Carcinoma", "Anal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 115,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00419159",
          "briefTitle": "Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-12"
          },
          "completionDateStruct": {
            "date": "2009-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 199,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03727789",
          "briefTitle": "CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-07-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-01-16",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Cutaneous Melanoma of the Extremity", "Advanced Sarcoma of the Extremity", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Recurrent Cutaneous Melanoma of the Extremity", "Recurrent Sarcoma of the Extremity", "Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 7,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      }
    ]
  }
}
